CD274 and melanoma: In a melanoma model, regorafenib has the most potent function, among a number of kinase inhibitors, in enhancing antitumor immunity via inhibiting IFN-γ-induced expression of PD-L1 and Indoleamine 2,3-dioxygenase 1 through RET–Src inhibition [31].